Beyond the Needle: Unlocking Hormone Therapy for Cervical Cancer Survivors

A recent investigation conducted by the University of Kentucky Markey Cancer Center indicates that while the majority of oncologists express a readiness to administer hormone therapy to cervical cancer patients experiencing premature menopause due to radiation treatment, practical impediments are hindering its widespread implementation. These findings have been published in JAMA Network Open.

For premenopausal women undergoing chemoradiotherapy for cervical cancer, a concurrent regimen of chemotherapy and radiation, the incidental radiation exposure to the ovaries frequently precipitates menopause. This condition manifests through distressing symptoms such as hot flashes, disrupted sleep patterns, and vaginal dryness. Although current clinical protocols sanction the utilization of hormonal therapy for alleviating menopausal symptoms in this demographic, empirical evidence suggests that its application remains suboptimal.

The research, spearheaded by Denise Fabian, M.D., a radiation oncologist at the Markey Cancer Center, with Dr. Morgan Levy serving as the lead author, delineates the obstacles encountered in the prescription process, offering insights that can guide enhancements in patient care.

To gather data, the research cohort disseminated a survey to 178 professionals in gynecologic and radiation oncology across the nation, affiliated with the Society for Gynecologic Oncology and the American Brachytherapy Society. The survey aimed to ascertain their perspectives and prescribing inclinations regarding hormonal therapy for cervical cancer patients receiving chemotherapy and radiation.

The inquiry revealed that an overwhelming 99.3% of gynecologic oncologists and 73.8% of radiation oncologists affirmed their willingness to consider prescribing hormonal therapy subsequent to chemoradiotherapy. Notwithstanding this expressed readiness, both groups cited significant challenges: the intricate nature of managing patients’ long-term care needs and a deficiency in awareness concerning established clinical guidelines.

“This investigation underscores a pivotal opportunity to fortify survivorship care for individuals diagnosed with cervical cancer, both within Kentucky and on a national scale,” stated Dr. Fabian.

Hormone therapy possesses the capability to substantially elevate not only the quality of life but also the long-term health prospects. It is imperative that we ensure greater access to this treatment for patients.”

Denise Fabian, University of Kentucky Markey Cancer Center

“Our findings demonstrate that oncologists are amenable to prescribing hormonal therapy to enhance the quality of life for our patients,” commented Dr. Levy. “We are eager to collaborate further with our multidisciplinary team specializing in survivorship and gynecologic oncology to devise interventions that will elevate the prevailing standard of care.”

The researchers indicate that future endeavors will concentrate on augmenting awareness of published guidelines and identifying strategies to streamline the prescribing process for clinicians, with the ultimate objective of facilitating broader patient access to care that is demonstrably safe and efficacious.